The Alberta Cancer Foundation announced a $35-million investment in cancer clinical trials on Monday, marking one of the largest research commitments in the organization's history. The funding aims to accelerate immunotherapy trials and other experimental treatments across the province, targeting improved access for patients.
Funding to support multiple centres
The donation will boost clinical trials at Calgary's Riddell Centre for Cancer Immunotherapy and Owerko Family Centre for Clinical Trials, as well as at Edmonton's Cross Cancer Centre and a centre in Lethbridge. Lethbridge will focus on research using advanced MRI imaging to reduce radiation sessions, according to the foundation.
Wendy Beauchesne, CEO of the Alberta Cancer Foundation, described clinical trials as "the bridge between the lab discovery and a living patient." She added, "We are living through one of the most hopeful, transformative eras in cancer care."
Patient impact and access
The foundation's funding provides Albertans access to more than 200 active cancer clinical trials at any given time. Last week, University of Calgary researchers unveiled a trial involving enhanced immunotherapy to attack solid cancerous tumours.
Kent B., a former cancer patient who benefited from the work of the Alberta Cancer Foundation, spoke at the announcement. His lung tumours have either disappeared or been significantly reduced by two rounds of experimental therapy at the Arthur J.E. Child Comprehensive Cancer Centre. "Now, we have a strong ray of hope cutting through the clouds for our family," said Kent, who withheld his last name. He called for a more aggressive approach to clinical trials, stating, "The risk calculation must change for patients."
Reducing need to travel
Previously, families like Kent's often had to leave the city or province for experimental therapies, said Dr. Vishal Nivani, an oncology researcher. "This places an immense physical strain on a patient that's already battling a devastating diagnosis," Nivani said. "We refuse to accept this as a reality for all Albertans. Calgary, over the last years, has become an emerging leader nationally in early phase clinical trials."
Part of broader cancer strategy
The investment aligns with Alberta's 10-year cancer strategy, which prioritizes clinical trials as a key pillar. The $35-million commitment covers a five-year clinical trial window, according to the foundation.
